[1] F. Gao et al., "Multi-site dynamic recording for Aβ oligomers-induced Alzheimer's disease in vitro based on neuronal network chip," Biosens. Bioelectron. 133, 183–191 (2019).

[2] E. McDade, R. J. Bateman, "Stop Alzheimer's before it starts," Nature 547(7662), 153–155 (2017).

[3] C. A. Lane, J. Hardy, J. M. Schott, "Alzheimer's disease," Eur. J. Neurol. 25(1), 59–70 (2018).

[4] L. M. Ittner, J. G€otz, "Amyloid-β and tau - a toxic pas de deux in Alzheimer's disease," Nat. Rev. Neurosci. 12(2), 65–72 (2011).

[5] M. Citron, "Strategies for disease modification in Alzheimer's disease," Nat. Rev. Neurosci. 5(9), 677–685 (2004).

[6] K. R. Brunden, J. Q. Trojanowski, V. M. Lee, "Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies," Nat. Rev. Drug Discov. 8(10), 783–793 (2009).

[7] R. A. Stelzmann et al., "An English translation of Alzheimer's 1907 paper, "über eine eigenartige erkankung der hirnrinde"," Clin Anat. 8(6), 429–431 (1995).

[8] C. L. Masters et al., "Amyloid plaque core protein in Alzheimer disease and Down syndrome," Proc. Natl. Acad. Sci. USA 82(12), 4245–4249 (1985).

[9] I. Grundke-Iqbal et al., "Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology," Proc. Natl. Acad. Sci. USA 83(13), 4913–4917 (1986).

[10] K. Blennow, "Cerebrospinal fluid protein biomarkers for Alzheimer's disease," NeuroRx 1(2), 213–225 (2004).

[11] K. Blennow, H. Hampel, "CSF markers for incipient Alzheimer's disease," Lancet Neurol. 2(10), 605–613 (2003).

[12] P. D. Mehta et al., "Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease," Arch. Neurol. 57(1), 100–105 (2000).

[13] O. Hansson et al., "Prediction of Alzheimer's disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment," Dement. Geriatr. Cogn. Disord. 23(5), 316–320 (2007).

[14] P. Lewczuk et al., "The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: Evidence of a novel carboxyterminally elongated Aβ peptide," Rapid Commun. Mass Spectrom. 17(12), 1291–1296 (2003).

[15] C. Haass, H. Steiner, "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?," Nat. Neurosci. 4(9), 859–860 (2001).

[16] W. L. Klein, "ADDLs & protofibrils - the missing links?," Neurobiol. Aging 23(2), 231–235 (2002).

[17] B. Caughey, P. T. Lansbury, "Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders," Annu. Rev. Neurosci. 26, 267–298 (2003).

[18] T. K. Khan, D. L. Alkon, "Peripheral biomarkers of Alzheimer's disease," J. Alzheimer's Dis. 44(3), 729–744 (2015).

[19] G. D. Rabinovici et al., "Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia," JAMA 321(13), 1286–1294 (2019).

[20] J. C. Lee et al., "Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers," Exp. Mol. Med. 51(5), 1–10 (2019).

[21] J. Fortea et al., "Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: A cross-sectional study," Lancet Neurol. 17(10), 860–869 (2018).

[22] L. Schneider, "A resurrection of aducanumab for Alzheimer's disease," Lancet Neurol. 19(2), 111–112 (2020).

[23] G. Tibbling, H. Link, S. Ohman, "Principles of albumin and IgG analyses in neurological disorders: I: Establishment of reference values," Scand. J. Clin. Lab. Invest. 37(5), 385–390 (1977).

[24] "Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease": The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group," Neurobiol. Aging 19(2), 109–116 (1998).

[25] D. Strozyk et al., "CSF Aβ 42 levels correlate with amyloid-neuropathology in a populationbased autopsy study," Neurology 60(4), 652–656 (2003).

[26] T. Tapiola et al., "Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain," Arch. Neurol. 66(3), 382–389 (2009).

[27] E. Niemantsverdriet et al., "The cerebrospinal fluid Aβ1β42/Aβ1β40 ratio improves concordance with amyloid-PET for diagnosing Alzheimer's disease in a clinical setting," J. Alzheimer's Dis. 60(2), 561–576 (2017).

[28] V. Vandermeeren et al., "Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay," J. Neurochem. 61(5), 1828–1834 (1993).

[29] K. Blennow et al., "Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?," Mol. Chem. Neuropathol. 26(3), 231–245 (1995).

[30] C. Vigo-Pelfrey et al., "Elevation of microtubuleassociated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease," Neurology 45(4), 788–793 (1995).

[31] H. Fukumoto et al., "β-Secretase protein and activity are increased in the neocortex in Alzheimer disease," Arch. Neurol. 59(9), 1381–1389 (2002).

[32] L. B. Yang et al., "Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease," Nat. Med. 9(1), 3–4 (2003).

[33] H. Zetterberg et al., "Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease," Arch. Neurol. 65(8), 1102–1107 (2008).

[34] A. Olsson et al., "Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients," Exp. Neurol. 183(1), 74–80 (2003).

[35] P. Lewczuk et al., "Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study," Mol. Psychiatry 15(2), 138–145 (2010).

[36] N. S. Schoonenboom et al., "Amyloidβ 38, 40, and 42 species in cerebrospinal fluid: More of the same?," Ann. Neurol. 58(1), 139–142 (2005).

[37] E. Portelius et al., "An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid," Neurosci. Lett. 409(3), 215–219 (2006).

[38] S. Mruthinti et al., "Autoimmunity in Alzheimer's disease: Increased levels of circulating IgGs binding Aβ and RAGE peptides," Neurobiol. Aging 25(8), 1023–1032 (2004).

[39] S. Brettschneider et al., "Decreased serum amyloid β1β42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1β42 peptide," Biol. Psychiatry 57(7), 813–816 (2005).

[40] B. T. Hyman et al., "Autoantibodies to amyloid-β and Alzheimer's disease," Ann. Neurol. 49(6), 808–810 (2001).

[41] O. F. Laterza et al., "Identification of novel brain biomarkers," Clin. Chem. 52(9), 1713–1721 (2006).

[42] T. J. Montine et al., "F2 -isoprostanes as biomarkers of late-onset Alzheimer's disease," J. Mol. Neurosci. 33(1), 114–119 (2007).

[43] T. J. Montine et al., "Cerebrospinal fluid aβ42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in agematched controls," Arch. Pathol. Lab. Med. 125(4), 510–512 (2001).

[44] M. Brys et al., "Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment," Neurobiol. Aging 30(5), 682–690 (2009).

[45] L. Cheng et al., "Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment," Mol. Psychiatry 20(10), 1188–1196 (2015).

[46] Z. Yan et al., "Presymptomatic increase of an extracellular RNA in blood plasma associates with the development of Alzheimer's disease," Curr. Biol. 30(10), 1771–1782. e1–e3 (2020).

[47] Z. Y. Cai et al., "Exosomes: A novel therapeutic target for Alzheimer's disease?," Neural Regen. Res. 13(5), 930–935 (2018).

[48] M. Otto et al., "Decreased β-amyloid1β42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease," Neurology 54(5), 1099–1102 (2000).

[49] M. Sj€ogren et al., "Decreased CSF-β-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by disparate mechanisms," Dement. Geriatr. Cogn. Disord. 13(2), 112–118 (2002).

[50] F. Hulstaert et al., "Improved discrimination of AD patients using β-amyloide1β42T and tau levels in CSF," Neurology 52(8), 1555–1562 (1999).

[51] M. Sj€ogren et al., "CSF levels of tau, β-amyloid1β42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging," J. Neural Transm. (Vienna) 107(5), 563–579 (2000).

[52] K. Kanemaru, N. Kameda, H. Yamanouchi, "Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies," Neurology 54(9), 1875–1876 (2000).

[53] E. Kapaki et al., "CSF tau protein and β-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population," Eur. J. Neurol. 10(2), 119–128 (2003).

[54] N. R€osler, I. Wichart, K. A. Jellinger, "Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients," J. Neural Transm. (Vienna) 108(2), 231–246 (2001).

[55] E. Kapaki et al., "Highly increased CSF tau protein and decreased β-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?," J. Neurol. Neurosurg. Psychiatry 71(3), 401–403 (2001).

[56] C. Mulder et al., "CSF markers related to pathogenetic mechanisms in Alzheimer's disease," J. Neural Transm. (Vienna) 109(12), 1491–1498 (2002).

[57] N. Andreasen et al., "Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment," Neurosci. Lett. 273(1), 5–8 (1999).

[58] H. Lee et al., "Alzheimer's disease diagnosis using misfolding proteins in blood," Dement. Neurocogn. Disord. 19(1), 1–18 (2020).

[59] B. Shui et al., "A novel electrochemical aptamerantibody sandwich assay for the detection of tau-381 in human serum," Analyst 143(15), 3549–3554 (2018).

[60] C. Deng et al., "An electrochemical aptasensor for amyloid-β oligomer based on double-stranded DNA as "conductive spring"," Microchim. Acta 187(4), 239 (2020).

[61] Y. Zhao et al., "A simple aptasensor for Aβ40 oligomers based on tunable mismatched base pairs of dsDNA and graphene oxide," Biosens. Bioelectron. 149, 111840 (2020).

[62] N. Xia et al., "Electrochemical detection of amyloid-β oligomers based on the signal amplification of a network of silver nanoparticles," ACS Appl. Mater. Interfaces 8(30), 19303–19311 (2016).

[63] C. Li et al., "A simple approach to quantitative determination of soluble amyloid-β peptides using a ratiometric fluorescence probe," Biosens. Bioelectron. 142, 111518 (2019).

[64] H. T. Ngoc Le et al., "Sensitive electrochemical detection of amyloid β peptide in human serum using an interdigitated chain-shaped electrode," Biosens. Bioelectron. 144, 111694 (2019).

[65] X. Zhang et al., "Robust and universal SERS sensing platform for multiplexed detection of Alzheimer's disease core biomarkers using PAapt-AuNPs conjugates," ACS Sens. 4(8), 2140–2149 (2019).

[66] A. Nabers et al., "Amyloid-β-secondary structure distribution in cerebrospinal fluid and blood measured by an immuno-infrared-sensor: A biomarker candidate for Alzheimer's disease," Anal. Chem. 88(5), 2755–2762 (2016).

[67] D. Li, M. M. Mielke, "An update on blood-based markers of Alzheimer's disease using the SiMoA platform," Neurol. Ther. 8(Suppl 2), 73–82 (2019).

[68] F. Xing et al., "Structural and functional studies of erythrocyte membrane-skeleton by single-cell and single-molecule techniques," J. Innov. Opt. Health Sci. 12(1), 1830004 (2019).

[69] K. S. Park, "Nucleic acid aptamer-based methods for diagnosis of infections," Biosens. Bioelectron. 102, 179–188 (2018).

[70] G. Zhu, X. Chen, "Aptamer-based targeted therapy," Adv. Drug Deliv. Rev. 134, 65–78 (2018).

[71] Y. Kim et al., "Comparative analyses of plasma amyloid-β levels in heterogeneous and monomerized states by interdigitated microelectrode sensor system," Sci. Adv. 5(4), eaav1388 (2019).

[72] D. H. Wilson et al., "The Simoa HD-1 analyzer: A novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing," J. Lab. Autom. 21(4), 533–547 (2016).

[73] J.-C. Park et al., "Plasma tau/amyloid-β1β42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease," Brain 142(5), 771–786 (2019).

[74] M. M. Mielke et al., "Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography," Alzheimer's Dement. 14 (8), 989–997 (2018).

[75] C. Z. J. Lim et al., "Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition," Nat. Commun. 10(1), 1144 (2019).

[76] K. S. Hong, M. A. Yaqub, "Application of functional near-infrared spectroscopy in the healthcare industry," J. Innov. Opt. Health Sci. 12(6), 1930012 (2019).

[77] K. Kim et al., "Clinically accurate diagnosis of Alzheimer's disease via multiplexed sensing of core biomarkers in human plasma," Nat. Commun. 11(1), 119 (2020).

[78] P. Seubert et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," Nature 359(6393), 325–327 (1992).

[79] L. Mucke, D. J. Selkoe, "Neurotoxicity of amyloid β-protein: synaptic and network dysfunction," Cold Spring Harb. Perspect. Med. 2(7), a006338 (2012).

[80] W. E. Van Nostrand et al., "Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients," Proc. Natl. Acad. Sci. USA 89(7), 2551–2555 (1992).

[81] M. Farlow et al., "Low cerebrospinal-fluid concentrations of soluble amyloid β-protein precursor in hereditary Alzheimer's disease," Lancet 340 (8817), 453–454 (1992).

[82] W. A. van Gool et al., "Concentrations of amyloid β protein in cerebrospinal fluid of patients with Alzheimer's disease," Ann. Neurol. 37(2), 277–279 (1995).

[83] J. T. Jarrett, E. P. Berger, P. T. Lansbury, Jr., "The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease," Biochemistry 32(18), 4693–4697 (1993).

[84] E. Portelius et al., "A novel pathway for amyloid precursor protein processing," Neurobiol. Aging 32 (6), 1090–1098 (2011).

[85] D. Beher et al., "Generation of C-terminally truncated amyloid-β peptides is dependent on gammasecretase activity," J. Neurochem. 82(3), 563–575 (2002).

[86] D. M. Hartley et al., "Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons," J. Neurosci. 19(20), 8876–8884 (1999).

[87] D. M. Walsh et al., "Amyloid β-protein fibrillogenesis: Structure and biological activity of proto-fibrillar intermediates," J. Biol. Chem. 274(36), 25945–29552 (1999).

[88] R. V. Ward et al., "Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of β-amyloid peptide," Biochem. J. 348, 137–144 (2000).

[89] A. Nabers et al., "Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease," Alzheimer's Dement. (Amst.) 11, 257–263 (2019).

[90] L. Zhang et al., "Dynamic changes in the levels of amyloid-β 42 species in the brain and periphery of APP/PS1 mice and their significance for Alzheimer's disease," Front. Mol. Neurosci. 14, 723317 (2021), doi: 10.3389/fnmol.2021.723317.

[91] M. Shoji et al., "Combination assay of CSF tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease," J. Neurol. Sci. 158(2), 134–140 (1998).

[92] P. J. Kahle et al., "Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF," Neurology 54(7), 1498–1504 (2000).

[93] Y. Morikawa et al., "Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics," Alcohol Clin. Exp. Res. 23(4), 575–577 (1999).

[94] N. Andreasen et al., "Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample," Neurology 53(7), 1488–1494 (1999).

[95] J. G€otz et al., "Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform," EMBO J. 14(7), 1304–1313 (1995).

[96] K. Santacruz et al., "Tau suppression in a neurodegenerative mouse model improves memory function," Science 309(5733), 476–481 (2005).

[97] J. G€otz, L. M. Ittner, S. Kins, "Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?," J. Neurochem. 98(4), 993–1006 (2006).

[98] L. M. Ittner, Y. D. Ke, J. G€otz, "Phosphorylated tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease," J. Biol. Chem. 284(31), 20909–20916 (2009).

[99] E. Vanmechelen et al., "Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization," Neurosci. Lett. 285(1), 49–52 (2000).

[100] Y. Y. Hu et al., "Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay," Am. J. Pathol. 160(4), 1269–1278 (2002).

[101] M. Riemenschneider et al., "Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias," Mol. Psychiatry 8(3), 343–347 (2003).

[102] K. Nakamura et al., "Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease," Cell 149(1), 232–244 (2012).

[103] J. Luna-Munoz et al., "Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease," J. Alzheimer's Dis. 12(4), 365–375 (2007).

[104] S. Janelidze et al., "Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia," Nat. Med. 26(3), 379–386 (2020).

[105] E. H. Thijssen et al., "Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration," Nat. Med. 26(3), 387–397 (2020).

[106] R. M. Holsinger et al., "Increased β-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects," Ann. Neurol. 55(6), 898–899 (2004).

[107] Z. Zhong et al., "Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment," Arch. Gen. Psychiatry 64(6), 718–726 (2007).

[108] E. Portelius et al., "Determination of β-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry," J. Proteome Res. 5(4), 1010–1016 (2006).

[109] A. Nath et al., "Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer's disease patients and Aβ antibodies can enhance Aβ neurotoxicity: Implications for disease pathogenesis and vaccine development," Neuromolecular Med. 3(1), 29–39 (2003).

[110] Y. Du et al., "Reduced levels of amyloid β-peptide antibody in Alzheimer disease," Neurology 57(5), 801–805 (2001).

[111] M. Britschgi et al., "Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease," Proc. Natl. Acad. Sci. USA 106(29), 12145–12150 (2009).

[112] J. M. Lee et al., "The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients," Clin. Chem. 54(10), 1617–1623 (2008).

[113] R. L. Friede, T. Samorajski, "Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice," Anat. Rec. 167(4), 379–387 (1970).

[114] M. Sj€ogren et al., "Neurofilament protein in cerebrospinal fluid: a marker of white matter changes," J. Neurosci. Res. 66(3), 510–516 (2001).

[115] A. Agren-Wilsson et al., "CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus," Acta Neurol. Scand. 116(5), 333–339 (2007).

[116] J. M. Ringman et al., "Biochemical markers in persons with preclinical familial Alzheimer disease," Neurology 71(2), 85–92 (2008).

[117] S. Nagaraj et al., "microRNA diagnostic panel for Alzheimer's disease and epigenetic trade-off between neurodegeneration and cancer," Ageing Res. Rev. 49, 125–143 (2019).

[118] K. Blennow, M. J. de Leon, H. Zetterberg, "Alzheimer's disease," Lancet 368(9533), 387–403 (2006).

[119] M. R. Brier et al., "Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease," Sci. Transl. Med. 8(338), 338ra66 (2016).

[120] C. R. Jack, Jr., "Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play," Radiology 263(2), 344–361 (2012).

[121] V. Valotassiou et al., "Clinical evaluation of brain perfusion SPECT with Brodmann areas mapping in early diagnosis of Alzheimer's disease," J. Alzheimer's Dis. 47(3), 773–785 (2015).

[122] V. Valotassiou et al., "Perfusion SPECT studies with mapping of Brodmann areas in differentiating Alzheimer's disease from frontotemporal degeneration syndromes," Nucl. Med. Commun. 33(12), 1267–1276 (2012).

[123] N. L. Foster et al., "FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease," Brain 130, 2616–2635 (2007).

[124] H. Braak, E. Braak, "Frequency of stages of Alzheimer-related lesions in different age categories," Neurobiol. Aging 18(4), 351–357 (1997).

[125] C. C. Rowe et al., "Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging," Neurobiol. Aging 31(8), 1275–1283 (2010).

[126] E. Giacobini, G. Gold, "Alzheimer disease therapy - moving from amyloid-β to tau," Nat. Rev. Neurol. 9(12), 677–686 (2013).

[127] V. Valotassiou et al., "SPECT and PET imaging in Alzheimer's disease," Ann. Nucl. Med. 32(9), 583–593 (2018).

[128] C. R. Jack, Jr., et al., "Longitudinal tau PET in ageing and Alzheimer's disease," Brain 141(5), 1517–1528 (2018).

[129] A. Mueller et al., "Tau PET imaging with 18F-PI- 2620 in patients with Alzheimer disease and healthy controls: A first-in-humans study," J. Nucl. Med. 61(6), 911–919 (2020).

[130] W. D. Brenowitz et al., "Cerebral amyloid angiopathy and its co-occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes," Neurobiol. Aging 36(10), 2702–2708 (2015).

[131] B. Holmberg et al., "Cerebrospinal fluid Aβ42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy," Mov. Disord. 18(2), 186–190 (2003).

[132] R. Motter et al., "Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease," Ann. Neurol. 38(4), 643–648 (1995).

[133] K. Blennow, E. Vanmechelen, H. Hampel, "CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease," Mol. Neurobiol. 24(1–3), 87–97 (2001).

[134] C. Bancher et al., "Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease," Brain Res. 477(1–2), 90–99 (1989).

[135] K. Ishiguro et al., "Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease," Neurosci. Lett. 270(2), 91–94 (1999).

[136] A. Nakamura et al., "High performance plasma amyloid-β biomarkers for Alzheimer's disease," Nature 554(7691), 249–254 (2018).

[137] M. C. Irizarry, "Biomarkers of Alzheimer disease in plasma," NeuroRx 1(2), 226–234 (2004).

[138] N. R. Graff-Radford et al., "Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease," Arch. Neurol. 64(3), 354–362 (2007).

[139] R. Mayeux et al., "Plasma Aβ40 and Aβ42 and Alzheimer's disease: Relation to age, mortality, and risk," Neurology 61(9), 1185–1190 (2003).

[140] N. Pomara et al., "Selective reductions in plasma Aβ 1-42 in healthy elderly subjects during longitudinal follow-up: A preliminary report," Am. J. Geriatr. Psychiatry 13(10), 914–917 (2005).

[141] M. van Oijen et al., "Plasma Aβ1β40 and Aβ1β42 and the risk of dementia: A prospective case-cohort study," Lancet Neurol. 5(8), 655–660 (2006).

[142] Y. M. Kuo et al., "High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer's disease," Biochem. Biophys. Res. Commun. 257 (3), 787–791 (1999).

[143] H. Englund et al., "Sensitive ELISA detection of amyloid-β protofibrils in biological samples," J. Neurochem. 103(1), 334–345 (2007).

[144] D. Sehlin et al., "Antibody-based PET imaging of amyloid β in mouse models of Alzheimer's disease," Nat. Commun. 7, 10759 (2016).

[145] S. Tucker et al., "The murine version of BAN2401 (mAb158) selectively reduces amyloid-β proto-fibrils in brain and cerebrospinal fluid of tg-ArcSwe mice," J. Alzheimer's Dis. 43(2), 575–588 (2015).

[146] H. Luo et al., "Design and applications of bispecific heterodimers: molecular imaging and beyond," Mol. Pharm. 11(6), 1750–1761 (2014).

[147] L. Zhang et al., "Development and characterization of double-antibody sandwich ELISA for detection of Zika virus infection," Viruses 10(11), 634 (2018).

[148] L. Zhang et al., "Instrument-free and visual detection of Salmonella based on magnetic nanoparticles and an antibody probe immunosensor," Int. J. Mol. Sci. 20(18), 4645 (2019).

[149] A. Nisonoff, F. C. Wissler, L. N. Lipman, "Properties of the major component of a peptic digest of rabbit antibody," Science 132(3441), 1770–1771 (1960).

[150] A. F. Labrijn et al., "Bispecific antibodies: a mechanistic review of the pipeline," Nat. Rev. Drug Discov. 18(8), 585–608 (2019).

[151] S. Syvanen et al., "A bispecific tribody PET radioligand for visualization of amyloid-β protofibrils - a new concept for neuroimaging," Neuroimage 148, 55–63 (2017).

[152] H. Luo et al., "ImmunoPET and near-infrared fluorescence imaging of pancreatic cancer with a dual-labeled bispecific antibody fragment," Mol. Pharm. 14(5), 1646–1655 (2017).

[153] H. Luo et al., "Dual targeting of tissue factor and CD105 for preclinical PET imaging of pancreatic cancer," Clin. Cancer Res. 22(15), 3821–3830 (2016).

[154] H. Luo et al., "Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry," Proc. Natl. Acad. Sci. USA 112 (41), 12806–12811 (2015).

[155] S. Shi et al., "Chelator-free labeling of layered double hydroxide nanoparticles for in vivo PET imaging," Sci. Rep. 5, 16930 (2015).

[156] R. C. Petersen, "How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture," Neurology 91(9), 395–402 (2018).

[157] B. C. Dickerson et al., "The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals," Cereb. Cortex 19(3), 497–510 (2009).

[158] C. Stenh et al., "Amyloid-β oligomers are ineffi- ciently measured by enzyme-linked immunosorbent assay," Ann. Neurol. 58(1), 147–150 (2005).

[159] T. Yang et al., "New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF," Alzheimer's Dement. 9(2), 99–112 (2013).

[160] H. Li et al., "A general way to assay protein by coupling peptide with signal reporter via supermolecule formation," Anal. Chem. 85(2), 1047–1052 (2013).

[161] L. Liu et al., "Electrochemical detection of amyloid-β oligomer with the signal amplification of alkaline phosphatase plus electrochemical–chemical–chemical redox cycling," J. Electroanal. Chem. 754, 40–45 (2015).

[162] M. K. Kang et al., "Label-free detection of ApoE4-mediated β-amyloid aggregation on single nanoparticle uncovering Alzheimer's disease," Biosens. Bioelectron. 72, 197–204 (2015).

[163] L. Guerrini et al., "SERS detection of amyloid oligomers on metallorganic-decorated plasmonic beads," ACS Appl. Mater. Interfaces 7(18), 9420–9428 (2015).

[164] Y. Zhang et al., "Optical penetration of surfaceenhanced micro-scale spatial offset Raman spectroscopy in turbid gel and biological tissue," J. Innov. Opt. Health Sci. 14(4), 2141001 (2021).

[165] L. Zhu et al., "Selective amyloid β oligomer assay based on abasic site-containing molecular beacon and enzyme-free amplification," Biosens. Bioelectron. 78, 206–212 (2016).

[166] J. V. Rushworth et al., "A label-free electrical impedimetric biosensor for the specific detection of Alzheimer's amyloid-β oligomers," Biosens. Bioelectron. 56, 83–90 (2014).

[167] A. J. Veloso et al., "Electrochemical immunosensors for effective evaluation of amyloid-β modulators on oligomeric and fibrillar aggregation processes," Anal. Chem. 86(10), 4901–4909 (2014).

[168] S. Ling et al., "Development of ELISA and colloidal gold immunoassay for tetrodotoxin detection based on monoclonal antibody," Biosens. Bioelectron. 71, 256–260 (2015).

[169] Y. Wang et al., "Rapid and sensitive detection of the food allergen glycinin in powdered milk using a lateral flow colloidal gold immunoassay strip test," J. Agric. Food Chem. 63(8), 2172–2178 (2015).

[170] X. Huang et al., "Membrane-based lateral flow immunochromatographic strip with nanoparticles as reporters for detection: A review," Biosens. Bioelectron. 75, 166–180 (2016).

[171] L. Hong et al., "High performance immunochromatographic assay for simultaneous quantitative detection of multiplex cardiac markers based on magnetic nanobeads," Theranostics 8(22), 6121–6131 (2018).

[172] M. Andersson et al., "Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report," J. Neurol. Neurosurg. Psychiatry 57(8), 897–902 (1994).

[173] K. Blennow et al., "Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors," Acta Neurol. Scand. 81(4), 323–326 (1990).

[174] K. Blennow et al., "Intrathecal synthesis of immunoglobulins in patients with Alzheimer's disease," Eur. Neuropsychopharmacol. 1(1), 79–81 (1990).

[175] D. Galasko et al., "High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype," Arch. Neurol. 55(7), 937–945 (1998).

[176] A. M. Fagan et al., "Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans," Ann. Neurol. 59(3), 512–519 (2006).

[177] A. Forsberg et al., "PET imaging of amyloid deposition in patients with mild cognitive impairment," Neurobiol. Aging 29(10), 1456–1465 (2008).

[178] S. Barao et al., "BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid," Curr. Alzheimer Res. 10(7), 671–678 (2013).

[179] S. D. Mulder et al., "BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology," J. Alzheimer's Dis. 20(1), 253–260 (2010).

[180] M. Ikeda et al., "CSF levels of Aβ1-38/Aβ1-40/Aβ1-42 and 11C PiB-PET studies in three clinical variants of primary progressive aphasia and Alzheimer's disease," Amyloid 21(4), 238–245 (2014).

[181] K. M. Kim et al., "Increased urinary F2-isoprostanes levels in the patients with Alzheimer's disease," Brain Res. Bull. 64(1), 47–51 (2004).

[182] M. Maruyama et al., "Cerebrospinal fluid amyloid β1β42 levels in the mild cognitive impairment stage of Alzheimer's disease," Exp. Neurol. 172(2), 433–436 (2001).

[183] M. Kanai et al., "Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan," Ann. Neurol. 44(1), 17–26 (1998).

[184] H. Arai et al., "No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia," Neurosci. Lett. 256(3), 174–176 (1998).

[185] M. Sj€ogren et al., "The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process," Dement. Geriatr. Cogn. Disord. 12(4), 257–264 (2001).

[186] H. Hampel et al., "Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease," Brain Res. 823(1–2), 104–112 (1999).

[187] T. Nishimura et al., "Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan," Methods Find. Exp. Clin. Pharmacol. 20(3), 227–235 (1998).

[188] L. M. Shaw et al., "Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects," Ann. Neurol. 65(4), 403–413 (2009).

[189] H. Pekeles et al., "Development and validation of a salivary tau biomarker in Alzheimer's disease," Alzheimer's Dement. (Amst.) 11, 53–60 (2019).

[190] C. M. Gao et al., "Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease," PLoS ONE 5(12), e15725 (2010).

[191] R. Kohnken et al., "Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients," Neurosci. Lett. 287(3), 187–190 (2000).

[192] K. Buerger et al., "Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231," Am. J. Psychiatry 160(2), 376–379 (2003).

[193] S. M. Rosso et al., "Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations," Arch. Neurol. 60(9), 1209–1213 (2003).

[194] K. Nagga et al., "Cerebrospinal fluid phospho-tau, total tau and β-amyloid1β42 in the differentiation between Alzheimer's disease and vascular dementia," Dement. Geriatr. Cogn. Disord. 14(4), 183–190 (2002).

[195] C. Eckerstr€om et al., "Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment," Dement. Geriatr. Cogn. Disord. 29(4), 294–300 (2010).

[196] J. Hertze et al., "Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical followup study of 4.7 years," J. Alzheimer's Dis. 21(4), 1119–1128 (2010).

[197] P. Buchhave et al., "Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia," Arch. Gen. Psychiatry 69(1), 98–106 (2012).

[198] N. Mattsson et al., "Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease," Ann. Clin. Transl. Neurol. 1(8), 534–543 (2014).

[199] L. Parnetti et al., "Performance of aβ1β40, aβ1β42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment," J. Alzheimer's Dis. 29(1), 229–238 (2012).

[200] J. A. Monge Argilβes et al., "A comparison of early diagnostic utility of Alzheimer disease biomarkers in brain magnetic resonance and cerebrospinal fluid," Neurologia 29(7), 397–401 (2014).

[201] P. Sch€onknecht et al., "Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease," Neurosci. Lett. 339(2), 172–174 (2003).

[202] C. Briani et al., "Combined analysis of CSF βA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data," J. Neural Transm. (Vienna) 109(3), 393–398 (2002).

[203] Y. A. L. Pijnenburg et al., "Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration," Neurology 60(2), 353–354 (2003).

[204] T. Tapiola et al., "CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease," Neurology 50(1), 169–174 (1998).

[205] M. Shoji et al., "Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group," Neurobiol. Aging 23(3), 363–370 (2002).

[206] M. Sj€ogren et al., "Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD," Neurology 54(10), 1960–1964 (2000).

[207] A. Wallin et al., "Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia," Dement. Geriatr. Cogn. Disord. 16(4), 200–207 (2003).

[208] H. Hampel et al., "Value of CSF β-amyloid1β42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment," Mol. Psychiatry 9(7), 705–710 (2004).

[209] H. Hampel et al., "Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity," J. Neural Transm. (Vienna) 111(3), 247–272 (2004).

[210] L. M. Bloudek et al., "Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease," J. Alzheimer's Dis. 26(4), 627–645 (2011).

[211] K. Wada-Isoe et al., "Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study," J. Neurol. Sci. 260(1–2), 33–37 (2007).

[212] O. Hansson et al., "Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a followup study," Lancet Neurol. 5(3), 228–234 (2006).

[213] A. J. Mitchell, "CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies," J. Neurol. Neurosurg. Psychiatry 80(9), 966–975 (2009).

[214] H. Arai et al., "Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease," Ann. Neurol. 38(4), 649–652 (1995).

[215] M. Ingelsson et al., "P3-076: CSF tau levels and APOE€4 carriership predict the progression of mild cognitive impairment to Alzheimer's disease," Alzhemier's Dement. 4(4SPart 16), T540 (2008).

[216] M. Riemenschneider et al., "Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration," Neurology 58(11), 1622–1628 (2002).

[217] K. Buerger et al., "Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231," Arch. Neurol. 59(8), 1267–1272 (2002).

[218] N. Mattsson et al., "CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment," JAMA 302(4), 385–393 (2009).

[219] M. Sj€ogren et al., "Both total and phosphorylated tau are increased in Alzheimer's disease," J. Neurol. Neurosurg. Psychiatry 70(5), 624–630 (2001).

[220] A. Maddalena et al., "Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42," Arch. Neurol. 60(9), 1202–1206 (2003).

[221] K. Bürger nβee Buch et al., "Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old patients with Alzheimer's disease compared with controls," Neurosci. Lett. 277(1), 21–24 (1999).

[222] N. Itoh et al., "Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease," Ann. Neurol. 50(2), 150–156 (2001).

[223] A. Kurz et al., "Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease," Alzheimer Dis. Assoc. Disord. 12(4), 372–377 (1998).

[224] N. Andreasen et al., "Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study," J. Neurol. Neurosurg. Psychiatry 64(3), 298–305 (1998).

[225] N. R€osler, I. Wichart, K. A. Jellinger, "Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease," J. Neurol. Neurosurg. Psychiatry 60(2), 237–238 (1996).

[226] E. N. Kapaki et al., "Cerebrospinal fluid tau, phospho-tau181 and β-amyloid1β42 in idiopathic normal pressure hydrocephalus: A discrimination from Alzheimer's disease," Eur. J. Neurol. 14(2), 168–173 (2007).

[227] K. Buerger et al., "Validation of Alzheimer's disease CSF and plasma biological markers: The multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI)," Exp. Gerontol. 44(9), 579–585 (2009).

[228] O. Hansson, "Biomarkers for neurodegenerative diseases," Nat. Med. 27(6), 954–963 (2021).

[229] M. Maruyama et al., "Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls," Neuron 79(6), 1094–1108 (2013).